These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1471 related articles for article (PubMed ID: 28940194)

  • 21. HER2 overexpression increases sensitivity to gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, through inhibition of HER2/HER3 heterodimer formation in lung cancer cells.
    Hirata A; Hosoi F; Miyagawa M; Ueda S; Naito S; Fujii T; Kuwano M; Ono M
    Cancer Res; 2005 May; 65(10):4253-60. PubMed ID: 15899817
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Quantitative analysis of HER2-mediated effects on HER2 and epidermal growth factor receptor endocytosis: distribution of homo- and heterodimers depends on relative HER2 levels.
    Hendriks BS; Opresko LK; Wiley HS; Lauffenburger D
    J Biol Chem; 2003 Jun; 278(26):23343-51. PubMed ID: 12686539
    [TBL] [Abstract][Full Text] [Related]  

  • 23. β-Heregulin impairs EGF induced PLC-γ1 signalling in human breast cancer cells.
    Rommerswinkel N; Keil S; Adawy A; Hengstler JG; Niggemann B; Zänker KS; Dittmar T
    Cell Signal; 2018 Dec; 52():23-34. PubMed ID: 30165102
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Carboxyl group footprinting mass spectrometry and molecular dynamics identify key interactions in the HER2-HER3 receptor tyrosine kinase interface.
    Collier TS; Diraviyam K; Monsey J; Shen W; Sept D; Bose R
    J Biol Chem; 2013 Aug; 288(35):25254-25264. PubMed ID: 23843458
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Interplay of the iron-regulated metastasis suppressor NDRG1 with epidermal growth factor receptor (EGFR) and oncogenic signaling.
    Menezes SV; Sahni S; Kovacevic Z; Richardson DR
    J Biol Chem; 2017 Aug; 292(31):12772-12782. PubMed ID: 28615452
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A positive feedback loop between HER2 and ADAM12 in human head and neck cancer cells increases migration and invasion.
    Rao VH; Kandel A; Lynch D; Pena Z; Marwaha N; Deng C; Watson P; Hansen LA
    Oncogene; 2012 Jun; 31(23):2888-98. PubMed ID: 21986939
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Targeting the HER3 pseudokinase domain with small molecule inhibitors.
    Colomba A; Claus J; Gao F; George R; Fornili A; Cameron AJM
    Methods Enzymol; 2022; 667():455-505. PubMed ID: 35525551
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Her4 and Her2/neu tyrosine kinase domains dimerize and activate in a reconstituted in vitro system.
    Monsey J; Shen W; Schlesinger P; Bose R
    J Biol Chem; 2010 Mar; 285(10):7035-44. PubMed ID: 20022944
    [TBL] [Abstract][Full Text] [Related]  

  • 29. EGFR inhibitors prevent induction of cancer stem-like cells in esophageal squamous cell carcinoma by suppressing epithelial-mesenchymal transition.
    Sato F; Kubota Y; Natsuizaka M; Maehara O; Hatanaka Y; Marukawa K; Terashita K; Suda G; Ohnishi S; Shimizu Y; Komatsu Y; Ohashi S; Kagawa S; Kinugasa H; Whelan KA; Nakagawa H; Sakamoto N
    Cancer Biol Ther; 2015; 16(6):933-40. PubMed ID: 25897987
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Controlled dimerization of ErbB receptors provides evidence for differential signaling by homo- and heterodimers.
    Muthuswamy SK; Gilman M; Brugge JS
    Mol Cell Biol; 1999 Oct; 19(10):6845-57. PubMed ID: 10490623
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Coexpression patterns of EGFR, HER2, HER3 and HER4 in non-melanoma skin cancer.
    Krähn G; Leiter U; Kaskel P; Udart M; Utikal J; Bezold G; Peter RU
    Eur J Cancer; 2001 Jan; 37(2):251-9. PubMed ID: 11166154
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Myofibroblasts have an impact on expression, dimerization and signaling of different ErbB receptors in OSCC cells.
    Büttner R; Berndt A; Valkova C; Richter P; Korn A; Kosan C; Liebmann C
    J Recept Signal Transduct Res; 2017 Feb; 37(1):25-37. PubMed ID: 27051967
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Parsing ERK activation reveals quantitatively equivalent contributions from epidermal growth factor receptor and HER2 in human mammary epithelial cells.
    Hendriks BS; Orr G; Wells A; Wiley HS; Lauffenburger DA
    J Biol Chem; 2005 Feb; 280(7):6157-69. PubMed ID: 15572377
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Expression and Prognostic Significance of Human Epidermal Growth Factor Receptors 1, 2 and 3 in Periampullary Adenocarcinoma.
    Elebro J; Heby M; Warfvinge CF; Nodin B; Eberhard J; Jirström K
    PLoS One; 2016; 11(4):e0153533. PubMed ID: 27070783
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Anti-cancer effect of metformin by suppressing signaling pathway of HER2 and HER3 in tamoxifen-resistant breast cancer cells.
    Kim J; Lee J; Kim C; Choi J; Kim A
    Tumour Biol; 2016 May; 37(5):5811-9. PubMed ID: 26581908
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical significance of the expression of EGFR signaling pathway-related proteins in esophageal squamous cell carcinoma.
    Li JC; Zhao YH; Wang XY; Yang Y; Pan DL; Qiu ZD; Su Y; Pan JJ
    Tumour Biol; 2014 Jan; 35(1):651-7. PubMed ID: 24052437
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A central role for HER3 in HER2-amplified breast cancer: implications for targeted therapy.
    Lee-Hoeflich ST; Crocker L; Yao E; Pham T; Munroe X; Hoeflich KP; Sliwkowski MX; Stern HM
    Cancer Res; 2008 Jul; 68(14):5878-87. PubMed ID: 18632642
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Protein secretion in human mammary epithelial cells following HER1 receptor activation: influence of HER2 and HER3 expression.
    Zhang Y; Gonzalez RM; Zangar RC
    BMC Cancer; 2011 Feb; 11():69. PubMed ID: 21320340
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Polyfunctional anti-human epidermal growth factor receptor 3 (anti-HER3) antibodies induced by HER3 vaccines have multiple mechanisms of antitumor activity against therapy resistant and triple negative breast cancers.
    Osada T; Hartman ZC; Wei J; Lei G; Hobeika AC; Gwin WR; Diniz MA; Spector N; Clay TM; Chen W; Morse MA; Lyerly HK
    Breast Cancer Res; 2018 Aug; 20(1):90. PubMed ID: 30092835
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Chemoresistant tumor cell lines display altered epidermal growth factor receptor and HER3 signaling and enhanced sensitivity to gefitinib.
    Servidei T; Riccardi A; Mozzetti S; Ferlini C; Riccardi R
    Int J Cancer; 2008 Dec; 123(12):2939-49. PubMed ID: 18803287
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 74.